You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Login
Username:

Password:


Related Headlines

hVIVO secures Decoy Therapeutics consultancy contract for antiviral development

AstraZeneca reports trial results showing immunotherapy combinations reduce progression risk in liver cancer

Rallybio and Avenzo Therapeutics announce merger agreement and USD215m financing

IBA launches Cyclone iKure for industrial-scale Astatine-211 production

Circio and GenAssist announce gene therapy research collaboration for muscle diseases and in vivo cell therapy

Avacta reports encouraging early efficacy signals for AVA6000 in salivary gland cancer at ASCO 2026

TiumBio presents Phase 2a interim data for Tosposertib plus pembrolizumab at ASCO 2026

ImmVira reports 100% CRR at 9 months in bladder carcinoma in situ with MVR-T3011

CARsgen presents long-term satri-cel follow-up results at 2026 ASCO Annual Meeting

Hanmi signs licensing deal with Lilly for sonefpeglutide

AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer

Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines

FDA approves TREMFYA label expansion

Phanes Therapeutics reports updated Phase 2 results for spevatamig (PT886) in combination with chemotherapy

GSK reports positive phase III data for bepirovirsen in chronic hepatitis B

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026